Metropolis Healthcare has announced that its Board of Directors will convene on November 4, 2025, to review and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The board will also consider the declaration of an interim dividend, if any, on the company’s equity shares for the financial year 2025-26.
Board Meeting Announcement
A meeting of the Board of Directors of Metropolis Healthcare is scheduled for November 4, 2025. The primary agenda includes reviewing the financial performance of the company for the recent period.
Financial Results on the Agenda
During the meeting, the board will consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year which concluded on September 30, 2025. This review will provide stakeholders with insights into the company’s financial health and operational efficiency.
Interim Dividend Consideration
In addition to the financial results, the Board will also evaluate the possibility of declaring an interim dividend for the financial year 2025-26. This decision will depend on the company’s financial position and strategic priorities.
Trading Window Closure
In compliance with the company’s Code of Conduct for Prevention of Insider Trading, the trading window for dealing in the company’s securities is closed from October 1, 2025, to November 6, 2025 (both days inclusive). This measure ensures fairness and prevents any potential misuse of unpublished price-sensitive information.
Source: BSE
